JP2012504112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504112A5 JP2012504112A5 JP2011528301A JP2011528301A JP2012504112A5 JP 2012504112 A5 JP2012504112 A5 JP 2012504112A5 JP 2011528301 A JP2011528301 A JP 2011528301A JP 2011528301 A JP2011528301 A JP 2011528301A JP 2012504112 A5 JP2012504112 A5 JP 2012504112A5
- Authority
- JP
- Japan
- Prior art keywords
- phenylcarbamoyloxymethyl
- hydroxycarbamoyl
- diethyl
- methyl
- ammonium chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 10
- -1 4-hydroxycarbamoyl-phenylcarbamoyloxymethyl Chemical group 0.000 claims 5
- 230000002071 myeloproliferative effect Effects 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- QKSGNWJOQMSBEP-UHFFFAOYSA-N diethyl-[[6-[[4-(hydroxycarbamoyl)phenyl]carbamoyloxymethyl]naphthalen-2-yl]methyl]azanium;chloride Chemical compound [Cl-].C1=CC2=CC(C[NH+](CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 QKSGNWJOQMSBEP-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 235000019270 ammonium chloride Nutrition 0.000 claims 2
- 150000004682 monohydrates Chemical group 0.000 claims 2
- 206010028537 myelofibrosis Diseases 0.000 claims 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2008A001720 | 2008-09-29 | ||
| ITMI2008A001720A IT1392908B1 (it) | 2008-09-29 | 2008-09-29 | Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative |
| US19328308P | 2008-11-13 | 2008-11-13 | |
| US61/193,283 | 2008-11-13 | ||
| PCT/EP2009/062214 WO2010034693A1 (en) | 2008-09-29 | 2009-09-21 | Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504112A JP2012504112A (ja) | 2012-02-16 |
| JP2012504112A5 true JP2012504112A5 (enExample) | 2012-08-02 |
Family
ID=40810309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011528301A Pending JP2012504112A (ja) | 2008-09-29 | 2009-09-21 | フィラデルフィア陰性骨髄増殖性症候群のケアのためのヒストンデアセチラーゼ阻害剤の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20110294892A1 (enExample) |
| EP (1) | EP2344253B1 (enExample) |
| JP (1) | JP2012504112A (enExample) |
| KR (3) | KR20170124640A (enExample) |
| CN (1) | CN102164638A (enExample) |
| BR (1) | BRPI0913699A2 (enExample) |
| CA (1) | CA2738081C (enExample) |
| CY (1) | CY1115255T1 (enExample) |
| DK (1) | DK2344253T3 (enExample) |
| ES (1) | ES2478827T3 (enExample) |
| HR (1) | HRP20140499T1 (enExample) |
| IT (1) | IT1392908B1 (enExample) |
| PL (1) | PL2344253T3 (enExample) |
| PT (1) | PT2344253E (enExample) |
| SI (1) | SI2344253T1 (enExample) |
| SM (1) | SMT201400087B (enExample) |
| WO (1) | WO2010034693A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8217079B2 (en) * | 2010-03-26 | 2012-07-10 | Italfarmaco Spa | Method for treating Philadelphia-negative myeloproliferative syndromes |
| WO2015165975A1 (en) * | 2014-04-29 | 2015-11-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating myeloid neoplasias |
| TW201821105A (zh) | 2016-10-20 | 2018-06-16 | 美商弗瑪治療公司 | 使用ｈｄａｃ１１抑制劑之方法 |
| EP3583155B1 (en) * | 2017-02-20 | 2024-05-08 | Dow Silicones Corporation | Room-temperature-curable silicone composition and electric/electronic apparatus |
| US11535607B2 (en) | 2018-04-20 | 2022-12-27 | Valo Health, Inc. | Isoindolines as HDAC inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| IT1283637B1 (it) | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| ITMI20030063A1 (it) * | 2003-01-17 | 2004-07-18 | Italfarmaco Spa | Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico. |
| ITMI20030064A1 (it) * | 2003-01-17 | 2004-07-18 | Italfarmaco Spa | Uso dei derivati dell'acido idrossamico per la preparazione |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| US20080194681A1 (en) * | 2004-12-09 | 2008-08-14 | Kalypsys, Inc. | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease |
| EP1910342A1 (en) * | 2005-07-29 | 2008-04-16 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| CN101426903A (zh) | 2005-12-09 | 2009-05-06 | 麻省理工学院 | 基于细胞核形态鉴定并靶向肿瘤干细胞的方法 |
| WO2008058287A1 (en) * | 2006-11-10 | 2008-05-15 | Syndax Pharmaceuticals, Inc. | COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| WO2008082646A2 (en) * | 2006-12-28 | 2008-07-10 | The Johns Hopkins University | Histone deacetylase inhibitors, combination therapies and methods of use |
-
2008
- 2008-09-29 IT ITMI2008A001720A patent/IT1392908B1/it active
-
2009
- 2009-09-21 KR KR1020177031565A patent/KR20170124640A/ko not_active Ceased
- 2009-09-21 HR HRP20140499AT patent/HRP20140499T1/hr unknown
- 2009-09-21 CN CN2009801382462A patent/CN102164638A/zh active Pending
- 2009-09-21 SI SI200930963T patent/SI2344253T1/sl unknown
- 2009-09-21 WO PCT/EP2009/062214 patent/WO2010034693A1/en not_active Ceased
- 2009-09-21 BR BRPI0913699A patent/BRPI0913699A2/pt not_active Application Discontinuation
- 2009-09-21 CA CA2738081A patent/CA2738081C/en active Active
- 2009-09-21 PT PT97832513T patent/PT2344253E/pt unknown
- 2009-09-21 PL PL09783251T patent/PL2344253T3/pl unknown
- 2009-09-21 DK DK09783251.3T patent/DK2344253T3/da active
- 2009-09-21 JP JP2011528301A patent/JP2012504112A/ja active Pending
- 2009-09-21 KR KR1020117008487A patent/KR20110069075A/ko not_active Ceased
- 2009-09-21 EP EP09783251.3A patent/EP2344253B1/en active Active
- 2009-09-21 ES ES09783251.3T patent/ES2478827T3/es active Active
- 2009-09-21 KR KR1020167020675A patent/KR20160096721A/ko not_active Ceased
-
2011
- 2011-03-25 US US13/064,450 patent/US20110294892A1/en not_active Abandoned
-
2013
- 2013-10-07 US US14/047,391 patent/US9522127B2/en active Active
-
2014
- 2014-07-07 SM SM201400087T patent/SMT201400087B/xx unknown
- 2014-07-09 CY CY20141100514T patent/CY1115255T1/el unknown
-
2016
- 2016-11-09 US US15/346,926 patent/US20170049740A1/en not_active Abandoned
-
2021
- 2021-01-15 US US17/149,794 patent/US20210128512A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| JP2009525343A5 (enExample) | ||
| JP2010536849A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| EP2444072A3 (en) | Non-mucoadhesive film dosage forms | |
| JP2010503695A5 (enExample) | ||
| JP2013516442A5 (enExample) | ||
| JP2016539156A5 (enExample) | ||
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| JP2013505282A5 (enExample) | ||
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
| AU2012284627A8 (en) | Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans | |
| JP2010518168A5 (enExample) | ||
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2013516493A5 (enExample) | ||
| JP2012504112A5 (enExample) | ||
| JP2012524089A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| BRPI0912112B8 (pt) | composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica | |
| WO2011159100A2 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| IL207928A (en) | Pharmacotherapeutic agent that contains an active drug (mtx) and helps 2, 2-anhydropyrimidine to reduce and use mtx toxicity | |
| JP2005517040A5 (enExample) | ||
| JP2011500589A5 (enExample) | ||
| JP2009518415A5 (enExample) |